Pulmatrix (PULM) Competitors $6.52 -0.09 (-1.36%) Closing price 03:55 PM EasternExtended Trading$6.56 +0.04 (+0.61%) As of 06:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PULM vs. EXOZ, OCX, CRBP, BDTX, TCRX, PLRX, ANIX, VIGL, CRDL, and ELUTShould you be buying Pulmatrix stock or one of its competitors? The main competitors of Pulmatrix include Exozymes (EXOZ), OncoCyte (OCX), Corbus Pharmaceuticals (CRBP), Black Diamond Therapeutics (BDTX), TScan Therapeutics (TCRX), Pliant Therapeutics (PLRX), Anixa Biosciences (ANIX), Vigil Neuroscience (VIGL), Cardiol Therapeutics (CRDL), and Elutia (ELUT). These companies are all part of the "pharmaceutical products" industry. Pulmatrix vs. Exozymes OncoCyte Corbus Pharmaceuticals Black Diamond Therapeutics TScan Therapeutics Pliant Therapeutics Anixa Biosciences Vigil Neuroscience Cardiol Therapeutics Elutia Exozymes (NASDAQ:EXOZ) and Pulmatrix (NASDAQ:PULM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, community ranking, institutional ownership, analyst recommendations and media sentiment. Does the MarketBeat Community believe in EXOZ or PULM? Pulmatrix received 196 more outperform votes than Exozymes when rated by MarketBeat users. CompanyUnderperformOutperformExozymesN/AN/APulmatrixOutperform Votes19648.28% Underperform Votes21051.72% Does the media refer more to EXOZ or PULM? In the previous week, Pulmatrix had 1 more articles in the media than Exozymes. MarketBeat recorded 2 mentions for Pulmatrix and 1 mentions for Exozymes. Exozymes' average media sentiment score of 1.87 beat Pulmatrix's score of 1.44 indicating that Exozymes is being referred to more favorably in the media. Company Overall Sentiment Exozymes Very Positive Pulmatrix Positive Do institutionals & insiders hold more shares of EXOZ or PULM? 11.8% of Pulmatrix shares are owned by institutional investors. 0.6% of Pulmatrix shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is EXOZ or PULM more profitable? Exozymes has a net margin of 0.00% compared to Pulmatrix's net margin of -96.51%. Exozymes' return on equity of 0.00% beat Pulmatrix's return on equity.Company Net Margins Return on Equity Return on Assets ExozymesN/A N/A N/A Pulmatrix -96.51%-45.97%-30.72% Which has preferable valuation & earnings, EXOZ or PULM? Exozymes has higher earnings, but lower revenue than Pulmatrix. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioExozymesN/AN/AN/AN/AN/APulmatrix$7.81M3.05-$14.12M-$2.61-2.50 SummaryPulmatrix beats Exozymes on 5 of the 9 factors compared between the two stocks. Get Pulmatrix News Delivered to You Automatically Sign up to receive the latest news and ratings for PULM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PULM vs. The Competition Export to ExcelMetricPulmatrixPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.80M$6.84B$5.53B$7.93BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-2.477.3222.5118.54Price / Sales3.05241.49397.62103.34Price / CashN/A65.8538.1834.62Price / Book1.326.486.734.25Net Income-$14.12M$143.41M$3.22B$248.18M7 Day Performance-3.69%2.30%1.58%1.25%1 Month Performance6.19%7.14%4.05%3.76%1 Year Performance244.96%-2.61%15.75%5.28% Pulmatrix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PULMPulmatrix0.8234 of 5 stars$6.52-1.4%N/A+247.9%$23.80M$7.81M-2.4720Short Interest ↓Positive NewsEXOZExozymesN/A$11.21+4.5%N/AN/A$93.81MN/A0.0029OCXOncoCyte2.1766 of 5 stars$3.22-6.4%$4.42+37.2%+23.7%$92.09M$1.88M-0.73120News CoverageCRBPCorbus Pharmaceuticals4.0315 of 5 stars$7.50-7.2%$59.13+688.3%-79.8%$91.74MN/A-1.6040Upcoming EarningsBDTXBlack Diamond Therapeutics3.527 of 5 stars$1.60+0.6%$14.60+812.5%-69.5%$90.68MN/A-1.2090Upcoming EarningsNews CoveragePositive NewsTCRXTScan Therapeutics3.7651 of 5 stars$1.60flat$9.33+483.3%-79.2%$90.55M$2.82M-1.51100News CoveragePositive NewsPLRXPliant Therapeutics4.305 of 5 stars$1.47+0.7%$13.31+805.6%-86.5%$90.24M$1.58M-0.4490Upcoming EarningsNews CoveragePositive NewsANIXAnixa Biosciences2.0554 of 5 stars$2.80+1.4%$9.00+221.4%-6.1%$90.15M$210,000.00-7.185VIGLVigil Neuroscience3.4692 of 5 stars$1.82+1.7%$16.25+792.9%-19.5%$89.40MN/A-0.8840Upcoming EarningsNews CoverageCRDLCardiol Therapeutics2.1778 of 5 stars$1.08flat$8.40+677.8%-45.3%$89.22MN/A-2.7720Positive NewsELUTElutia3.3059 of 5 stars$2.18-6.4%$9.00+312.8%-16.6%$88.81M$24.38M-0.84180Upcoming EarningsShort Interest ↑News CoverageGap Up Related Companies and Tools Related Companies Exozymes Alternatives OncoCyte Alternatives Corbus Pharmaceuticals Alternatives Black Diamond Therapeutics Alternatives TScan Therapeutics Alternatives Pliant Therapeutics Alternatives Anixa Biosciences Alternatives Vigil Neuroscience Alternatives Cardiol Therapeutics Alternatives Elutia Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PULM) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored"I'm risking my reputation on this"I've stayed quiet for too long, but after everything I've uncovered about what's brewing in the 2025 crypto ma...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pulmatrix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pulmatrix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PULM Stock Free PULM Stock Alerts